Download Media Release

3: EMBARGOED MEDIA ADVISORY
STRICTLY UNDER EMBARGO UNTIL 12:00PM NOON ET (US) ON FRIDAY, APRIL 22, 2016
Region(s) of Interest: United States, Maryland
Institution(s): Johns Hopkins University School of Medicine
Zika is test case for brain organoid mini-reactors
The Zika virus epidemic comes at a time when new stem cell techniques
for studying the brain are being refined and tested. On April 22 in Cell,
Johns Hopkins University School of Medicine researchers unveil brainregion-specific organoids that show in three dimensions how the virus
affects the human brain. The organoid data support that Zika prefers to
infect neural stem cells and that the extent of damage differs depending on
time of infection.
Organoids are clumps of tissue grown in the laboratory that mimic how
organs naturally form. Brain organoids--also called mini-brains--have been
actively used in research for years, but they are limited by their high cost, lack of access for most labs, and
tricky protocols that prevent clear control experiments. The Hopkins group, led by Guo-li Ming and Hongjun
Song, solved these problems by 3D printing miniaturized spinning bioreactors to mass produce brain-regionspecific organoids from human stem cells.
Ming and Song were part of the team in early March that helped link Zika infection to neural stem cell death
(Cell Stem Cell, 10.1016/j.stem.2016.02.016), but those pilot experiments were done in two-dimensional tissue
cultures that may not fully recapitulate features in normal brain development. The bioreactors allowed the
researchers to do the studies they really wanted to carry out--namely, look at Zika infection in developing neural
tissues. "When the Zika crisis came up, we saw that we have the perfect system to study the impacts of the
virus," says Song, who directs the Stem Cell Program at John Hopkins Medicine Institute for Cell Engineering.
The mini-bioreactors were used to make three types of brain-region-specific organoids (forebrain, midbrain, and
hypothalamus), which survive and grow for up to 100 days. This time span allowed the researchers to induce
Zika infection during developmental stages equivalent to very early and mid-pregnancy. The 3D experiments
replicated previous work finding that the virus prefers to infect neural stem cells and supported clinical findings
that the developing brain is most at risk during the first trimester.
"The organoids are much smaller and they're not generating neurons efficiently when they are infected with the
Zika virus," says Ming, a Johns Hopkins Medicine professor of neurology. "At the later stages, you still see
preferred infection of the neural progenitor cells, although there is some infection of the neurons as well, and the
cell death and reduction in proliferation is consistent with what we saw in the 2D cultures."
"The data from the Zika virus really highlights the power of this model system where we can study different
stages of the disease and look at the mechanisms behind infection," Song says. "With the bioreactor, the model
now has power as a preclinical testing ground for potential therapies."
The researchers are making the technology in their Cell paper accessible to the scientific community and are
currently testing FDA-approved compounds on the organoids to see whether any can manage Zika infection,
with an additional future challenge being how to deliver a potential Zika therapy to the fetus.
###
This work was supported by grants from the National Institutes of Health and the Simons Foundation Autism
Research Initiative.
Cell, Qian and Nguyen et al.: "Brain-Region-Specific Organoids Using Mini-bioreactors for Modeling ZIKV
Exposure" http://www.cell.com/cell/fulltext/S0092-8674(16)304676. http://dx.doi.org/10.1016/j.cell.2016.04.032
Related Files
This Dropbox contains a PDF of the paper proof, the supplemental info and an image of a brain organoid
infected with Zika virus. ZIKV envelope protein is shown in green; neural progenitor cells marked by SOX2 are
shown in red; neurons marked by CTIP2 are shown in blue. (Credit: Xuyu Qian/Johns Hopkins
University): https://www.dropbox.com/sh/q54lmj7xuu6kn82/AABHEL1_5qlpm3LNl4tKvmq5a?dl=0
Author Contacts:
Guo-li Ming
Johns Hopkins University School of Medicine
[email protected]
+1 443-287-7498
Hongjun Song
Johns Hopkins University School of Medicine
[email protected]
+1 443-287-7499
Media Contact:
Shawna Williams
Johns Hopkins University School of Medicine
+1 410-955-8236
[email protected]